top of page

Skyhawk’s $80M Celgene deal expands remit to autoimmune

  • maura169
  • Nov 12, 2019
  • 1 min read


In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.



For more information visit:


SKYHAWK MEDIA CONTACT:

Maura McCarthy




 
 
 

Comentários


Small Molecules that Modify RNA Expression
Contact

Skyhawk Therapeutics, Inc.
180 3rd Ave., Fifth Floor
Waltham, MA 02451
United States

info@skyhawktx.com
1-617-858-0041

Skyhawk Therapeutics Europe, GmbH
Hochbergerstrasse 60I
Basel 4057 Switzerland
+41 (0) 61 512 15 20

Sitemap
  • X
  • LinkedIn

©2024 Skyhawk Therapeutics - All Rights Reserved

Skyhawk, SkyStar and triangle mark are federally registered trademarks owned by Skyhawk Therapeutics, Inc.

bottom of page